Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 3;11(6):506.
doi: 10.3390/jpm11060506.

Association of Matrix Metalloproteinases with Coronary Artery Calcification in Patients with CHD

Yana V Polonskaya  1 , Elena V Kashtanova  1 , Ivan S Murashov  2 , Evgenia V Striukova  1 , Alexey V Kurguzov  2 , Ekaterina M Stakhneva  1 , Viktoria S Shramko  1 , Nikolay A Maslatsov  1 , Aleksandr M Chernyavsky  2 , Yulia I Ragino  1
Affiliations

Association of Matrix Metalloproteinases with Coronary Artery Calcification in Patients with CHD

Yana V Polonskaya et al. J Pers Med. .

Abstract

This work is aimed at studying the relationship of matrix metalloproteinases with calcification of the coronary arteries. The study included 78 people with coronary heart disease (CHD) and 36 without CHD. Blood and samples of coronary arteries obtained as a result of endarterectomy were examined. Serum levels of metalloproteinases (MMP) MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-10, MMP-12, and MMP-13 were determined by multiplex analysis. In blood vessel samples, MMP-1, MMP-3, MMP-7, and MMP-9 were determined by enzyme immunoassay; MMP-9 expression was evaluated by immunohistochemistry. Patients with CHD had higher serum levels of MMP-1, MMP-7, and MMP-12. Blood levels of MMP-1 and MMP-3 were associated with calcium levels, MMP-9 with osteoprotegerin and osteonectin, MMP-7 and MMP-10 with osteoprotegerin, MMP-12 with osteocalcin, and MMP-13 with osteopontin. Calcified plaques had higher levels of MMP-1 and MMP-9 compared to plaques without calcification. The relative risk of coronary arteries calcification was associated with MMP-9, which is confirmed by the results of immunohistochemistry. The results obtained indicate the participation of some MMPs, and especially MMP-9, in the calcification processes. The study can serve as a basis for the further study of the possibility of using MMP-1, MMP-7 and MMP-12 as potential biomarkers of CHD.

Keywords: atherosclerosis; calcification; coronary heart disease; metalloproteinases; multiplex assay.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Figure 1
Figure 1
The concentration of MMP-1 and MMP-7 in the studied group, Me (25%; 75%).
Figure 2
Figure 2
The level of MMP-12 in the studied groups, Me (25%; 75%).
Figure 3
Figure 3
Atherosclerotic plaques of coronary arteries. (a) The unstable atherosclerotic plaque with calcification (magnification 100×; MMP9 immunostaining). MMP-9 expression in necrotic areas in the extracellular matrix along the periphery of the calcification core, and in thinned and damaged parts of the fine fibrous cap. (b) The stable atherosclerotic plaque without calcification (magnification 100×; MMP9 immunostaining). Lacks MMP-9 expression both in the atheromatous core and in the fibrous cap.
See this image and copyright information in PMC

References

    1. Roth G.A., Johnson C., Abajobir A., Abd-Allah F., Abera S.F., Abyu G., Ahmed M., Aksut B., Alam T., Alam K., et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. 2017;70:1–25. doi: 10.1016/j.jacc.2017.04.052. - DOI - PMC - PubMed
    1. Lee J.S., Basalyga D.M., Simionescu A., Isenburg J.C., Simionescu D.T., Vyavahare N.R. Elastin calcification in the rat subdermal model is accompanied by up-regulation of degradative and osteogenic cellular responses. Am. J. Pathol. 2006;168:490–498. doi: 10.2353/ajpath.2006.050338. - DOI - PMC - PubMed
    1. Beaudeux J.-L., Giral P., Bruckert E., Foglietti M.-J., Chapman M.J. Matrix metalloproteinases, inflammation and atherosclerosis: Therapeutic perspectives. Clin. Chem. Lab. Med. 2004;42:121–131. doi: 10.1515/CCLM.2004.024. - DOI - PubMed
    1. Kadoglou N.P., Daskalopoulou S.S., Perrea D., Liapis C. Matrix Metalloproteinases and Diabetic Vascular Complications. Angiology. 2005;56:173–189. doi: 10.1177/000331970505600208. - DOI - PubMed
    1. Uzui H., Harpf A., Liu M., Doherty T.M., Shukla A., Chai N.N., Tripathi P.V., Jovinge S., Wilkin D.J., Asotra K., et al. Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: Role of activated macrophages and inflammatory cytokines. Circulation. 2002;106:3024–3030. doi: 10.1161/01.CIR.0000041433.94868.12. - DOI - PubMed